Swiss drugmaker Roche leans into Trump tariff formula with $50bn promise to invest in U.S.

A man walks next to a sign for the Roche Holding AG headquarters on April 11, 2025 in Basel, Switzerland. Before US President Donald Trump postponed a range of imminent tariffs, Switzerland was facing a daunting 31% levy on most Swiss goods to imported to the United States, a higher rate than would have been imposed on European Union countries. Such a tariff would've been high damaging to iconic Swiss industries like chocolate and watchmaking. The reprieve will provide breathing room for Swiss officials looking to negotiate a deal with the US, although Swiss goods will still face a 10% tariff in the meantime, and the fate of a potential separate tariff on pharmaceuticals is unknown. (Credit: Sedat Suna/Getty Images)

Swiss pharmaceutical giant Roche has promised to export more medicine from the U.S. than it imports once a fresh $50 billion investment pledge across the States is rolled out, joining other European drugmakers in attempting to pre-empt more potential tariffs from the Trump administration.

Roche announced on Tuesday a new investment pledge that the group says would include expanding its manufacturing and distribution centers in Indiana, Pennsylvania, Massachusetts, and California. It is also planning a 900,000 square foot manufacturing facility at an unconfirmed location in the U.S., where it will develop its next generation weight loss medications.